{
  "api_version": "1",
  "request": {
    "url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Neoplasm&page=41",
    "query": {
      "condition": "Recurrent Neoplasm",
      "page": 41
    },
    "page_size": 10
  },
  "pagination": {
    "page": 41,
    "page_size": 10,
    "total_count": 9118,
    "total_pages": 912,
    "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Neoplasm&page=42&page_size=10",
    "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?condition=Recurrent+Neoplasm&page=40&page_size=10"
  },
  "source": "remote",
  "last_synced_at": "2026-11-01T22:06:36.206Z",
  "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.",
  "notes": [
    "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.",
    "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.",
    "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees."
  ],
  "trials": [
    {
      "nct_id": "NCT01939275",
      "title": "64Cu DOTA-Trastuzumab PET/CT in Studying Patients With Gastric Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "NA"
      ],
      "conditions": [
        "Adenocarcinoma of the Gastroesophageal Junction",
        "Diffuse Adenocarcinoma of the Stomach",
        "Intestinal Adenocarcinoma of the Stomach",
        "Mixed Adenocarcinoma of the Stomach",
        "Recurrent Gastric Cancer",
        "Stage IA Gastric Cancer",
        "Stage IB Gastric Cancer",
        "Stage IIA Gastric Cancer",
        "Stage IIB Gastric Cancer",
        "Stage IIIA Gastric Cancer",
        "Stage IIIB Gastric Cancer",
        "Stage IIIC Gastric Cancer",
        "Stage IV Gastric Cancer"
      ],
      "interventions": [
        {
          "name": "copper Cu 64-DOTA-trastuzumab",
          "type": "RADIATION"
        },
        {
          "name": "positron emission tomography",
          "type": "DEVICE"
        },
        {
          "name": "laboratory biomarker analysis",
          "type": "OTHER"
        },
        {
          "name": "Computed Tomography",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "RADIATION",
        "DEVICE",
        "OTHER",
        "PROCEDURE"
      ],
      "sponsor": "City of Hope Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 8,
      "start_date": "2014-11-19",
      "completion_date": "2024-08-05",
      "has_results": true,
      "last_update_posted_date": "2025-02-28",
      "last_synced_at": "2026-11-01T22:06:36.206Z",
      "location_count": 1,
      "location_summary": "Duarte, California",
      "locations": [
        {
          "city": "Duarte",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01939275"
    },
    {
      "nct_id": "NCT02581930",
      "title": "Ibrutinib in Treating Patients With Refractory Metastatic Cutaneous Melanoma",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Metastatic Melanoma",
        "Recurrent Cutaneous Melanoma",
        "Stage IV Cutaneous Melanoma AJCC v6 and v7"
      ],
      "interventions": [
        {
          "name": "Ibrutinib",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Pharmacogenomic Study",
          "type": "OTHER"
        },
        {
          "name": "Pharmacological Study",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2016-12-16",
      "completion_date": "2021-09-09",
      "has_results": true,
      "last_update_posted_date": "2026-08-11",
      "last_synced_at": "2026-11-01T22:06:36.206Z",
      "location_count": 13,
      "location_summary": "Los Angeles, California • Sacramento, California • Aurora, Colorado + 9 more",
      "locations": [
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Los Angeles",
          "state": "California"
        },
        {
          "city": "Sacramento",
          "state": "California"
        },
        {
          "city": "Aurora",
          "state": "Colorado"
        },
        {
          "city": "Tampa",
          "state": "Florida"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02581930"
    },
    {
      "nct_id": "NCT00874211",
      "title": "S0702: Osteonecrosis of the Jaw in Patients With Cancer Receiving Zoledronic Acid for Bone Metastases",
      "overall_status": "COMPLETED",
      "study_type": "OBSERVATIONAL",
      "phases": [],
      "conditions": [
        "Breast Cancer",
        "Lung Cancer",
        "Metastatic Cancer",
        "Multiple Myeloma",
        "Plasma Cell Neoplasm",
        "Prostate Cancer",
        "Unspecified Adult Solid Tumor, Protocol Specific"
      ],
      "interventions": [
        {
          "name": "assessment of therapy complications",
          "type": "PROCEDURE"
        }
      ],
      "intervention_types": [
        "PROCEDURE"
      ],
      "sponsor": "SWOG Cancer Research Network",
      "sponsor_class": "NETWORK",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": null,
        "maximum_age": "120 Years",
        "sex": "ALL",
        "summary": "Up to 120 Years"
      },
      "enrollment_count": 3571,
      "start_date": "2008-12",
      "completion_date": "2019-06",
      "has_results": false,
      "last_update_posted_date": "2019-07-05",
      "last_synced_at": "2026-11-01T22:06:36.206Z",
      "location_count": 451,
      "location_summary": "Anniston, Alabama • Mobile, Alabama • Anchorage, Alaska + 302 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        },
        {
          "city": "Fairbanks",
          "state": "Alaska"
        },
        {
          "city": "Jonesboro",
          "state": "Arkansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00874211"
    },
    {
      "nct_id": "NCT02163694",
      "title": "A Phase 3 Randomized, Placebo-controlled Trial of Carboplatin and Paclitaxel With or Without Veliparib (ABT-888) in HER2-negative Metastatic or Locally Advanced Unresectable BRCA-associated Breast Cancer",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Metastatic Breast Cancer"
      ],
      "interventions": [
        {
          "name": "Veliparib Placebo",
          "type": "DRUG"
        },
        {
          "name": "Veliparib",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Paclitaxel",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "AbbVie",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 513,
      "start_date": "2014-04-08",
      "completion_date": "2024-01-25",
      "has_results": true,
      "last_update_posted_date": "2025-02-19",
      "last_synced_at": "2026-11-01T22:06:36.206Z",
      "location_count": 56,
      "location_summary": "Gilbert, Arizona • Little Rock, Arkansas • Duarte, California + 48 more",
      "locations": [
        {
          "city": "Gilbert",
          "state": "Arizona"
        },
        {
          "city": "Little Rock",
          "state": "Arkansas"
        },
        {
          "city": "Duarte",
          "state": "California"
        },
        {
          "city": "Fresno",
          "state": "California"
        },
        {
          "city": "La Jolla",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT02163694"
    },
    {
      "nct_id": "NCT07867002",
      "title": "Assessing Survival Outcomes With Checkpoint Inhibition ExteNded vs Discontinued in Endometrial Cancer",
      "overall_status": "NOT_YET_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Endometrial Adenocarcinoma",
        "Metastatic Endometrial Cancer",
        "Endometrial Cancer",
        "Recurrent Endometrial Cancer"
      ],
      "interventions": [
        {
          "name": "anti-PD1 agent therapy - 1 year",
          "type": "DRUG"
        },
        {
          "name": "anti-PD1 agent therapy - 2 years",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "UNC Lineberger Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 140,
      "start_date": "2026-10",
      "completion_date": "2032-10",
      "has_results": false,
      "last_update_posted_date": "2026-10-15",
      "last_synced_at": "2026-11-01T22:06:36.206Z",
      "location_count": 6,
      "location_summary": "Cary, North Carolina • Chapel Hill, North Carolina • Garner, North Carolina + 2 more",
      "locations": [
        {
          "city": "Cary",
          "state": "North Carolina"
        },
        {
          "city": "Chapel Hill",
          "state": "North Carolina"
        },
        {
          "city": "Garner",
          "state": "North Carolina"
        },
        {
          "city": "Greensboro",
          "state": "North Carolina"
        },
        {
          "city": "Raleigh",
          "state": "North Carolina"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT07867002"
    },
    {
      "nct_id": "NCT05609253",
      "title": "Itraconazole to Prevent Recurrent Barrett's Esophagus",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "EARLY_PHASE1"
      ],
      "conditions": [
        "Barrett Oesophagitis With Dysplasia"
      ],
      "interventions": [
        {
          "name": "Itraconazole in capsule form",
          "type": "DRUG"
        },
        {
          "name": "Itraconazole in solution form",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "University of Kansas Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 10,
      "start_date": "2022-09-14",
      "completion_date": "2026-12-30",
      "has_results": false,
      "last_update_posted_date": "2026-06-18",
      "last_synced_at": "2026-11-01T22:06:36.206Z",
      "location_count": 1,
      "location_summary": "Kansas City, Kansas",
      "locations": [
        {
          "city": "Kansas City",
          "state": "Kansas"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05609253"
    },
    {
      "nct_id": "NCT00732745",
      "title": "Vandetanib, Oxaliplatin, and Docetaxel in Advanced Cancer of the Esophagus or Gastroesophageal Junction",
      "overall_status": "TERMINATED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1"
      ],
      "conditions": [
        "Adenocarcinoma of the Gastroesophageal Junction",
        "Esophageal Cancer"
      ],
      "interventions": [
        {
          "name": "docetaxel",
          "type": "DRUG"
        },
        {
          "name": "oxaliplatin",
          "type": "DRUG"
        },
        {
          "name": "vandetanib",
          "type": "DRUG"
        },
        {
          "name": "placebo",
          "type": "OTHER"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "Case Comprehensive Cancer Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 9,
      "start_date": "2008-10",
      "completion_date": null,
      "has_results": false,
      "last_update_posted_date": "2011-08-22",
      "last_synced_at": "2026-11-01T22:06:36.206Z",
      "location_count": 1,
      "location_summary": "Cleveland, Ohio",
      "locations": [
        {
          "city": "Cleveland",
          "state": "Ohio"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00732745"
    },
    {
      "nct_id": "NCT00085436",
      "title": "DC Vaccine Combined With IL-2 and IFNα-2a in Treating Patients With mRCC",
      "overall_status": "COMPLETED",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE2"
      ],
      "conditions": [
        "Kidney Cancer"
      ],
      "interventions": [
        {
          "name": "Aldesleukin,",
          "type": "BIOLOGICAL"
        },
        {
          "name": "autologous tumor cell vaccine",
          "type": "BIOLOGICAL"
        },
        {
          "name": "recombinant interferon alfa",
          "type": "BIOLOGICAL"
        }
      ],
      "intervention_types": [
        "BIOLOGICAL"
      ],
      "sponsor": "Dartmouth-Hitchcock Medical Center",
      "sponsor_class": "OTHER",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "ALL",
        "summary": "18 Years and older"
      },
      "enrollment_count": 18,
      "start_date": "2003-12",
      "completion_date": "2009-10",
      "has_results": true,
      "last_update_posted_date": "2018-06-26",
      "last_synced_at": "2026-11-01T22:06:36.206Z",
      "location_count": 1,
      "location_summary": "Lebanon, New Hampshire",
      "locations": [
        {
          "city": "Lebanon",
          "state": "New Hampshire"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT00085436"
    },
    {
      "nct_id": "NCT01272037",
      "title": "Tamoxifen Citrate, Letrozole, Anastrozole, or Exemestane With or Without Chemotherapy in Treating Patients With Invasive RxPONDER Breast Cancer",
      "overall_status": "ACTIVE_NOT_RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE3"
      ],
      "conditions": [
        "Breast Ductal Carcinoma In Situ",
        "Invasive Breast Carcinoma",
        "Multicentric Breast Carcinoma",
        "Multifocal Breast Carcinoma",
        "Synchronous Bilateral Breast Carcinoma"
      ],
      "interventions": [
        {
          "name": "Anastrozole",
          "type": "DRUG"
        },
        {
          "name": "Exemestane",
          "type": "DRUG"
        },
        {
          "name": "Laboratory Biomarker Analysis",
          "type": "OTHER"
        },
        {
          "name": "Letrozole",
          "type": "DRUG"
        },
        {
          "name": "Quality-of-Life Assessment",
          "type": "OTHER"
        },
        {
          "name": "Systemic Chemotherapy",
          "type": "DRUG"
        },
        {
          "name": "Tamoxifen Citrate",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG",
        "OTHER"
      ],
      "sponsor": "National Cancer Institute (NCI)",
      "sponsor_class": "NIH",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "18 Years",
        "maximum_age": null,
        "sex": "FEMALE",
        "summary": "18 Years and older · Female only"
      },
      "enrollment_count": 5018,
      "start_date": "2011-02-28",
      "completion_date": "2027-01-08",
      "has_results": true,
      "last_update_posted_date": "2026-10-26",
      "last_synced_at": "2026-11-01T22:06:36.206Z",
      "location_count": 1435,
      "location_summary": "Anniston, Alabama • Birmingham, Alabama • Mobile, Alabama + 881 more",
      "locations": [
        {
          "city": "Anniston",
          "state": "Alabama"
        },
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Mobile",
          "state": "Alabama"
        },
        {
          "city": "Anchorage",
          "state": "Alaska"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT01272037"
    },
    {
      "nct_id": "NCT05533775",
      "title": "A Study to Evaluate Glofitamab Monotherapy and Glofitamab + Chemoimmunotherapy in Pediatric and Young Adult Participants With Relapsed/Refractory Mature B-Cell Non-Hodgkin Lymphoma",
      "overall_status": "RECRUITING",
      "study_type": "INTERVENTIONAL",
      "phases": [
        "PHASE1",
        "PHASE2"
      ],
      "conditions": [
        "Mature B-Cell Non-Hodgkin Lymphoma"
      ],
      "interventions": [
        {
          "name": "Obinutuzumab",
          "type": "DRUG"
        },
        {
          "name": "Glofitamab",
          "type": "DRUG"
        },
        {
          "name": "Rituximab",
          "type": "DRUG"
        },
        {
          "name": "Ifosfamide",
          "type": "DRUG"
        },
        {
          "name": "Carboplatin",
          "type": "DRUG"
        },
        {
          "name": "Etoposide",
          "type": "DRUG"
        },
        {
          "name": "Tocilizumab",
          "type": "DRUG"
        }
      ],
      "intervention_types": [
        "DRUG"
      ],
      "sponsor": "Hoffmann-La Roche",
      "sponsor_class": "INDUSTRY",
      "healthy_volunteers": false,
      "eligibility": {
        "minimum_age": "6 Months",
        "maximum_age": "30 Years",
        "sex": "ALL",
        "summary": "6 Months to 30 Years"
      },
      "enrollment_count": 65,
      "start_date": "2022-11-16",
      "completion_date": "2032-11-30",
      "has_results": false,
      "last_update_posted_date": "2026-10-06",
      "last_synced_at": "2026-11-01T22:06:36.206Z",
      "location_count": 10,
      "location_summary": "Birmingham, Alabama • Oakland, California • Roseville, California + 6 more",
      "locations": [
        {
          "city": "Birmingham",
          "state": "Alabama"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Oakland",
          "state": "California"
        },
        {
          "city": "Roseville",
          "state": "California"
        },
        {
          "city": "Santa Clara",
          "state": "California"
        }
      ],
      "official_url": "https://clinicaltrials.gov/study/NCT05533775"
    }
  ]
}